Travel restrictions bite Bavarian as rabies vaccine sales plunge
At the end of Q1, Bavarian Nordic presented shrinking sales of vaccines Rabipur/Rabavert against rabies and Encepur against TBE.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
Danish biotechnology company Bavarian Nordic's vaccine against rabies has been tripped up by the covid-19 pandemic and resulting travel restrictions, the firm's Vice President Investor Relations & Communications Rolf Sass Sørensen tells Ritzau Finans following the publication of the firm's Q1 report.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Bavarian Nordic maintains guidance for 2021
For subscribers
.jpg&w=384&q=75)
